Cancer Health Services Research

Using clinical registries to improve outcomes for future patients | Dr Koen Degeling

Health and process outcomes captured in clinical registries provide valuable insights into real-world treatment patterns, but how can we use those data to evaluate current cancer treatments and inform treatment decisions for future patients?

Measuring adherence to the Optimal Care Pathway for people with melanoma | Karen Trapani

From diagnosis to surgical treatment, how long does the Optimal Care Pathway take, and does it impact patient outcomes?

Evaluating Clinical Utility of Complex Genomic Sequencing in Advanced Cancer | Sophie O'Haire

Exploring the clinical impact of complex genomic testing on overall survival in advanced & refractory cancer using a simulated control arm.

The opportunity of data-driven health services research to improve cancer outcomes | Prof Maarten IJzerman

Recent achievements in the Cancer Health Services Research group of the UMCCR, enabling the use of clinical and administrative data registries to optimise cancer outcomes.

Detecting circulating tumour DNA in localised prostate cancer | Associate Prof Bernie Pope

An overview of recent work in detecting ctDNA in individuals with localised prostate cancer, a context that has previously proven challenging.

Economic value assessment of next-generation sequencing technologies in blood cancers

Martin presents findings on a recent systematic review to highlight urgent need to remedy the gap between the health economic research and clinical practice for next-generation sequencing technologies in blood cancers.

Utilising population-level linked data to improve (genomics enabled) cancer outcomes in Victoria

Progress in the development of an enduring linked dataset and provides examples of utilising this data for improving genomics enabled precision oncology.

Immune-related adverse events and the role of emerging risk factors

Overview of immune-related adverse events from cancer immunotherapies and the role of risk factors to identify patients at high risk of treatment-related harm.

Establishing a Victorian linked dataset for budget impact modelling of new cancer treatments

Using real-world data, the group have established a framework to quantify the population health economic impact of new cancer treatments for colorectal cancer, non-small cell lung cancer and melanoma.

Health Economic Evidence for Liquid Biopsy Assays in Cancer Management

Mussab presents: Health Economic Evidence for Liquid Biopsy Assays in Cancer Management: A Systematic Literature Review.

Establishing a Victorian linked-dataset: what have we learned?

This seminar asks: what does it take to establish a linked-dataset and what have we learned from colorectal cancer care in Victoria so far?

Cure – at what cost? Implications of novel therapies in melanoma

In this seminar, Dr Soon outlines her current research including a novel approach to consumer engagement and results from a horizon scanning project to identify promising cancer medicines in the pipeline.